Joint Amgen/Novartis migraine drug will be a blockbuster! Forget about osteo drug, it will come on later. Look at NVS stock price--news about this drug is not discussed much by Amgen press but it has moved NVS stock up nicely! Amgen to follow once market makers have bought enough shares at low prices.
Per Caroline Chen over at Bloomberg News -- "$amgn sees cardiovascular safety signal in romo arch trial- now doesn't expect approval in 2017 (prev pdufa July)"
AMGN SHAREHOLDERS AND BIOTECH INVESTORS: BMY and MRK promising blockbuster PD1 Inhibitor Keytruda and Opdivo beginning combination trials with NWBO DC-Vax-L. NWBO shares already beginning to move up now as investors realize major positive announcements from 10 year brain cancer phase III trial are likely next week at ASCO.
Company already announced in February that it had met the Primary Progression Free Survival Endpoint and that not yet for Overall Survival but expected in this current timeframe.
Shares have been under extreme selling pressure from negative press by the usual short seller advocates.
NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached
BETHESDA, Md., Feb. 6, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a further update about the Compa
In the short-term AMGN does not seem to be like a good trade. Ive been struggling with this stock lately. Some of my other trades have been from awesomeS-TOCKS which are working out pretty well.
Looking forward to the FDA approval on Erenumab. I needed it, this roller-coasting AMGN stock is giving me migraine headache.
Funny how Yahoo and Barrons ignore good news about Amgen and constantly report and re-report old negative stories. Must be paid by power and well-connected shorts. As usual, brain dead SEC stands by to catch the 100 share insider sales like Martha Stewart. Barrons needs to make money somehow its publication is full of so called analysts stories that swindle the small retail investor read that #$%$.
This stock is so oversold buy buy buy buy
whooz yor daddy
BMO's analyst rating: ...The analysts cut their price target to $198 from $200 after probability-adjusting romosozumab revenues while reiterating an outperform rating, the analysts said in the note....
Kinda funny he cut PT by $2
See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio.
• BioLargo’s 10Q states their Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days • Woundcare market is over $6 Billion with high growth rate • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost • Sales could commence in first half of 2018 • Sales and or licensing agreement/s could be very significant • Company is now commercializing several other disruptive products in large markets
Dividend hunters beware, Amgen (NASDAQ:AMGN) will pay its upcoming dividend of $1.15 on the Thu 08 Jun 2017 and will start trading ex-dividend on the Mon 15 May 2017. Should dividend investors care? Today I’m going to investigate the latest data and analyze some metrics you shouldn’t overlook.
What is the ex-dividend date? If you purchase a stock on or after its ex-dividend date, you will not receive the next dividend payment. Instead, the seller gets the dividend. If you purchase before the ex-dividend date, you get the dividend.
CHRS soured 8.5 north due to Humira (ABBV) patent court case; AMGN will follow (8.5% or more north). It is a matter of days or weeks.
whooz yor daddy
#$%$???? The dow is up 165 and again all my biotechs are down today! What's going on at that shareholder meeting today?
3 fer 1 split makes good sense; this puppy weyy over-sold, no brainer
Amgen, Inc. (AMGN) to Issue Quarterly Dividend of $1.15 on June 8th
13 hours ago - Amgen, Inc. (NASDAQ:AMGN) announced a quarterly dividend on Tuesday, March 7th. Shareholders of record on Wednesday, May 17th will be paid a dividend ...
Charles A. Henriques NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration San Francisco Bay Area 500+ 500+ connections Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.
Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.
Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.
QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,
Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.
Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany
The Bank of New York Mellon has over 1/3 Billion dollars in faith in AMGN & investors should too :
Amgen Inc. (AMGN) filed a Form 8K - Entry Into a Definitive Agreement - with the U.S Securities and Exchange Commission on May 11, 2017.
On May 11, 2017, Amgen Inc. (the "Company") issued and sold $300,000,000 of its Senior Floating Rate Notes due 2019 (the "2019 Floating Rate Notes"), $300,000,000 of its Senior Floating Rate Notes due 2020 (the "2020 Floating Rate Notes" and, together with the 2019 Floating Rate Notes, the "Floating Rate Notes"), $700,000,000 of its 1.900% Senior Notes due 2019 (the "2019 Fixed Rate Notes"), $700,000,000 of its 2.200% Senior Notes due 2020 (the "2020 Fixed Rate Notes") and $1,500,000,000 of its 2.650% Senior Notes due 2022 (the "2022 Fixed Rate Notes" and, together with the 2019 Floating Rate Notes, the 2020 Floating Rate Notes, the 2019 Fixed Rate Notes and the 2020 Fixed Rate Notes, the "Notes"). The Notes are registered under an effective Registration Statement on Form S-3 (Registration No. 333-216060) (the "Registration Statement"), filed on February 14, 2017, and were issued pursuant to an indenture, dated as of May 22, 2014 (the "Indenture"), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee, and an officer's certificate, dated as of May 11, 2017 (the "Officer's Certificate"), setting forth the terms of the Notes. Net proceeds to the Company from the offering were approximately $3,483,548,000, after deducting underwriters' discounts and estimated offering expenses payable by the Company.
I believe AMGN has refinanced at a lower rate of interest in order to make a large acquisition. JMO, Dr. J
UPGRADED TO STRONG BUY: Amgen, Inc. (AMGN) Raised to “Strong-Buy” at Vetr Inc. - Markets Daily